In a Duchenne market beset by problems, Capricor data marks a bright spot

In a Duchenne market beset by problems, Capricor data marks a bright spot

Source: 
Pharma Voice
snippet: 

Capricor Therapeutics, a California-based biotech, recently announced its investigative treatment, deramiocel (CAP-1002), slowed Duchenne progression by almost 50% in patients who had taken the treatment for three years as part of its ongoing phase 2 HOPE-2 open-label extension study, according to Linda Marbán, Capricor’s CEO.